## Haitham Mirghani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10741257/publications.pdf

Version: 2024-02-01

430874 361022 1,230 35 18 35 citations g-index h-index papers 36 36 36 2388 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?. Clinical and Translational Radiation Oncology, 2018, 8, 4-11.	1.7	141
2	Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. Cancer Treatment Reviews, 2015, 41, 844-852.	7.7	110
3	Influence of Prophylactic Neck Dissection on Rate of Retreatment for Papillary Thyroid Carcinoma. World Journal of Surgery, 2013, 37, 1951-1958.	1.6	97
4	Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. Lancet Oncology, The, 2020, 21, e350-e359.	10.7	96
5	Human papilloma virus testing in oropharyngeal squamous cell carcinoma: What the clinician should know. Oral Oncology, 2014, 50, 1-9.	1.5	85
6	Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice. Modern Pathology, 2015, 28, 1518-1527.	5.5	78
7	Postradioiodine Treatment Whole-Body Scan in the Era of 18-Fluorodeoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with Elevated Serum Thyroglobulin Levels. Thyroid, 2012, 22, 832-838.	4.5	71
8	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. Cancer Treatment Reviews, 2018, 65, 54-64.	7.7	51
9	Postoperative Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: An Important Imaging Modality in Patients with Aggressive Histology of Differentiated Thyroid Cancer. Thyroid, 2015, 25, 437-444.	4.5	45
10	Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test. Oral Oncology, 2016, 62, 101-108.	1.5	40
11	HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue?. Frontiers in Oncology, 2020, 10, 1751.	2.8	39
12	Sinonasal cancer: Analysis of oncological failures in 156 consecutive cases. Head and Neck, 2014, 36, 667-674.	2.0	38
13	Nodal recurrence of sinonasal cancer: Does the risk of cervical relapse justify a prophylactic neck treatment?. Oral Oncology, 2013, 49, 374-380.	1.5	33
14	Evaluation of the efficacy of the 4 tests (p16 immunochemistry, polymerase chain reaction, DNA, and) Tj ETQq0 0 cohort of 348 French squamous cell carcinomas. Human Pathology, 2018, 78, 63-71.	0 rgBT /O	verlock 10 T
15	Prevalence and characteristics of HPV-driven oropharyngeal cancer in France. Cancer Epidemiology, 2019, 61, 89-94.	1.9	31
16	Does smoking alter the mutation profile of human papillomavirus–driven head and neck cancers?. European Journal of Cancer, 2018, 94, 61-69.	2.8	29
17	Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer. Oral Oncology, 2018, 82, 108-114.	1.5	26
18	The musculocutaneous infrahyoid flap: surgical key points. European Archives of Oto-Rhino-Laryngology, 2012, 269, 1213-1217.	1.6	20

#	Article	IF	CITATIONS
19	A predictive transcriptomic signature of oropharyngeal cancer according to HPV16 status exclusively. Oral Oncology, 2014, 50, 1025-1034.	1.5	19
20	Should a neck dissection be performed on patients with cNO adenoid cystic carcinoma? A REFCOR propensity score matching study. European Journal of Cancer, 2020, 130, 250-258.	2.8	19
21	Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 32-37.	4.5	16
22	Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review. European Archives of Oto-Rhino-Laryngology, 2015, 272, 1577-1586.	1.6	15
23	Sinonasal squamous cell carcinoma without clinical lymph node involvement. Strahlentherapie Und Onkologie, 2016, 192, 537-544.	2.0	14
24	Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric study. European Journal of Cancer, 2021, 143, 168-177.	2.8	13
25	HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population. Modern Pathology, 2018, 31, 1645-1652.	5.5	13
26	Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study. Oral Oncology, 2021, 112, 105041.	1.5	11
27	Relationship between the time to locoregional recurrence and survival in laryngeal squamous-cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2017, 274, 2267-2271.	1.6	10
28	Genomics and precision surgery for head and neck squamous cell carcinoma. Cancer Letters, 2020, 481, 45-54.	7.2	10
29	Human Papillomavirus Type 16 Oropharyngeal Cancers in Lymph Nodes as a Marker of Metastases. JAMA Otolaryngology, 2011, 137, 910.	1.2	9
30	Oropharyngeal cancers: Significance of HPV16 detection in neck lymph nodes. Journal of Clinical Virology, 2013, 57, 120-124.	3.1	6
31	Correlation between the duration of locoregional control and survival in T1–T2 oropharyngeal cancer patients. European Archives of Oto-Rhino-Laryngology, 2019, 276, 1161-1166.	1.6	4
32	Smoking and papillomavirus DNA in patients with p16â€positive N3 oropharyngeal squamous cell carcinoma. Head and Neck, 2019, 41, 1039-1045.	2.0	3
33	The coagulome of Head and Neck Squamous Cell Carcinoma. Oral Oncology, 2021, 114, 105068.	1.5	3
34	Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study. Oral Oncology, 2021, 122, 105503.	1.5	3
35	Anatomic Variability of the Upper Mediastinal Lymph Node Level VII. World Journal of Surgery, 2016, 40, 1899-1903.	1.6	1